4 results
To provide continued bevacizumab therapy as single agent or in combination with an anti-cancer drug to patients with cancer, who were previously enrolled in a F. Hoffmann-La Roche (Roche)/ Genentech sponsored bevacizumab study (i.e. the Parent, P-…
To assess the immunomodulatory effects of erythromycin and clindamycin in healthy volunteers.
General- To determine the safety of OTL38 in IBD and rheumatoid arthritis patients by monitoring of vital signs during tracer infusion and evaluating possible (severe) adverse events (SAE/AEs).RA- To determine the feasibility of molecular…
1. The primary objective of this phase I/II clinical trial is to evaluate the safety and toxicity of ACT plus nivolumab according to CTCAE 4.0 criteria. Toxicity grade 3 or less and SAE related to treatment but that does not result in treatment…